CLEC12A Molekülinformation
Molecule Name
C-Type lectin domain family 12 member A
Molekülalias
CLEC12A,MICL,CLL-1,CLL1,DCAL2,DCAL-2,CD371
Drug Development Progress
Anzahl der klinischen Arzneimittel26
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
CD371 Antigen，C-Type Lectin-Like Molecule 1，MICL，CD371，CLEC12A，DCAL2，DCAL-2，Dendritic cell-associated lectin 2，C-Type Lectin Domain Family 12 Member A，Myeloid Inhibitory C-Type Lectin-Like Receptor，CLL-1，CLL1，C-Type Lectin Domain Family 12， Member A，C-Type Lectin-Like Molecule-1，C-Type Lectin Protein CLL-1
Molekülhintergrund
CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years. The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.
CLEC12A Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| CLL1/CD33/CD38/CD7 CAR-T cell therapy | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Leukemia, Myeloid | Details | |
| ARD-103 | ARD-103; ARD103 | Phase 2 Clinical | ARCE Therapeutics Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Anti-CLL1 CAR-T (Guangzhou Bio-Gene) | BG-1805; BG1805 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Anti-CLL1 CAR T cell therapy(Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
| CLL1 modulator CAR-NK cell therapy (Hangzhou Qihan Biotech/Zhejiang University) | Phase 1 Clinical | Otech Co Ltd | Leukemia, Myeloid, Acute | Details | |
| anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| Novel CAR-ITNK Cells Targeting CD70 and CLL1 therapy (Tongji Hospital) | Phase 1 Clinical | Tongji Hospital | Leukemia, Myeloid, Acute | Details | |
| A-CAR028 | A-CAR028 | Phase 1 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details |
| JY-017 | JY017; JY-017 | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Leukemia, Myeloid, Acute | Details |
| QL-325 | QL-325 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd, Qlsf Biotherapeutics Inc | Leukemia, Myeloid, Acute | Details |
| Anti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital) | Phase 1 Clinical | Shanghai Jiao Tong University Affiliated First People'S Hospital | Leukemia, Myeloid, Acute | Details | |
| Dual CLL1/CD38 targeting CAR-T cell therapy (Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech) | Phase 1 Clinical | Hangzhou Qihan Jiyin Biotechnology Co Ltd, Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan) | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Neoplasm, Residual | Details | |
| CD371 CAR IL18 T cell therapy (Memorial Sloan Kettering Cancer Center/Takeda) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Takeda Development Center Americas Inc | Leukemia, Myeloid, Acute | Details | |
| ADCLEC.syn1 CAR T cells therapy (Memorial Sloan-Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Myeloid, Acute | Details | |
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| QLF-32101 | QLF32101; QLF-32101 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| CLL1 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR T-cell Therapy(Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details |